Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Sidoti Micro-Cap Virtual Investor Conference on January 22, 2026 at 1:45 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Sidoti Micro-Cap Virtual Investor Conference on January 22, 2026 at 1:45 PM ET. CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing clinical trial of lead compound PH-762 for treatment of skin cancers. The presentation is available via live webcast and the CEO will hold one-on-one investor meetings during the conference on Jan 21–22, 2026. Registration is free and open to non-clients.
Details
News Market Reaction – PHIO
On Jan 15, the day this news came out, PHIO closed 0.89% above the previous close.
Data tracked by StockTitan Argus for the Jan 15 session.
Key Figures
- Presentation date
- January 22, 2026
- Sidoti Micro-Cap Virtual Investor Conference
- Presentation time
- 1:45 PM ET
- Phio’s conference presentation slot
- Conference start
- January 21, 2026 8:30 AM ET
- Start of one-on-one meetings window
- Conference end
- January 22, 2026 5:00 PM ET
- End of one-on-one meetings window
Historical Context
-
FDA accepted nonclinical protocol and toxicology study planned for Q1 2026.
-
Completed enrollment in Phase 1b PH-762 trial across five dose cohorts.
-
Upcoming podium talk on INTASYL siRNA drug technology at industry congress.
-
Q3 2025 results, strong PH-762 responses, and financings lifting cash runway.
-
Planned SITC poster with Phase 1b PH-762 clinical results for skin cancers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sirna medical
gene silencing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ET
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers.
"All stakeholders and investors are invited to join the presentation and register for one-on-one meetings to learn more about Phio Pharmaceuticals in our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Phio's presentation will begin at 1:45 PM ET on January 22, 2026 and can be accessed live here: WEBCAST LINK FOR PHIO'S PRESENTATION: Webinar Registration - Zoom
Mr. Bitterman will also host one-on-one meetings with investors at the conference, taking place on Wednesday Jan 21, 2026 8:30 AM ET through Thursday Jan 22, 2026 at 5:00 PM ET. Registration is free and you don't need to be a Sidoti client. REGISTRATION LINK FOR ONE-ON-ONE MEETINGS: www.sidoti.com/events.
About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")
In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280343
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.